IGE

NeuroPace Announces Preliminary Unaudited Revenue for Fourth Quarter and Full Year 2023 and Provides Business Updates

Retrieved on: 
Monday, January 8, 2024
Patient, Responsive neurostimulation device, Conference, Biotechnology, Epilepsy, FDA, Data analysis, Idiopathic generalized epilepsy, Health, RNS, Clinical trial, ATM, Hemispherectomy, IGE, Machine learning, Growth, Investment, Project, Safety, Intelligence, Pharmaceutical industry

NeuroPace plans to release its fourth quarter and full year 2023 financial results in early March of 2024.

Key Points: 
  • NeuroPace plans to release its fourth quarter and full year 2023 financial results in early March of 2024.
  • Preliminary unaudited revenue expected to be between $17.5 million and $18.0 million for the fourth quarter ended December 31, 2023, representing growth of 37% to 41% versus the fourth quarter of 2022.
  • Total full year 2023 revenue expected to be between $64.9 million and $65.4 million grew 43% to 44% versus full year 2022 and came in well above initial 2023 revenue guidance of $50-$52 million.
  • To support these efforts, the Company plans to make some incremental additions to its sales and support teams.

NeuroPace Announces Early Completion of Patient Enrollment in NAUTILUS Pivotal Study

Retrieved on: 
Thursday, December 21, 2023
Consciousness, Patient, Responsive neurostimulation device, Injury, Food, Epilepsy, Depression, FDA, SUDEP, Idiopathic generalized epilepsy, Ageing, Trial of the century, Brain, RNS, IGE, IDE, Death, Social, Seizure, Nursing

MOUNTAIN VIEW, Calif., Dec. 21, 2023 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a commercial, growth-stage, medical technology company focused on transforming the lives of people living with epilepsy, today announced the completion of the patient enrollment goal in its NAUTILUS pivotal study for the treatment of idiopathic generalized epilepsy (IGE) more than one quarter ahead of schedule.

Key Points: 
  • “We are extremely proud to have completed patient enrollment in our NAUTILUS pivotal study significantly ahead of schedule,” said Martha Morrell, M.D., NeuroPace’s Chief Medical Officer.
  • “We would like to recognize and thank the clinical investigators and patients that have enrolled in this important and groundbreaking trial.
  • Forty percent of drug-refractory epilepsy patients are diagnosed with generalized epilepsy, and NeuroPace believes that this early patient enrollment milestone is reflective of the excitement amongst patients and clinicians in potentially addressing this significant unmet need with the RNS System.
  • If the study achieves its primary endpoints, NeuroPace plans to submit a PMA Supplement and also intends to publish findings in a peer-reviewed medical journal.

NeuroPace and the RNS System Showcased at the 77th American Epilepsy Society (AES) Annual Meeting

Retrieved on: 
Friday, December 1, 2023
Responsive neurostimulation device, Epilepsy, Generalization, LGS, AES, Hemispherectomy, IGE, Patient, RCT

“The Society’s annual meeting is the largest conference in the field of epilepsy in the U.S.,” said Martha Morrell, M.D., NeuroPace’s Chief Medical Officer.

Key Points: 
  • “The Society’s annual meeting is the largest conference in the field of epilepsy in the U.S.,” said Martha Morrell, M.D., NeuroPace’s Chief Medical Officer.
  • “We look forward to collaborating with the many healthcare providers, scientists, and others from all over the world who are gathering in Orlando to promote better outcomes for people with epilepsy.
  • We will host various presentations and events highlighting our RNS System and look forward to engaging with the broader scientific community in the epilepsy field.”
    Over 50 original scientific presentations and posters regarding the RNS System will be presented throughout the meeting, as well as a number of general meeting sessions that include how the RNS System provides an important therapy option for the treatment of drug resistant epilepsy.
  • These presentations, posters, and events involve key opinion leaders as well as early career scientists and clinicians, all of whom aim to improve the lives of patients living with drug-resistant epilepsy.

Pontimax Technologies's Comprehensive Solution For Agile Inferencing & Reasoning Decision Support at The Cloud "Edge"

Retrieved on: 
Tuesday, September 12, 2023
Cloud, Knowledge, Capability, Information repository, Compact, Pattern, IGE, Dynamics, Local area network, Memory, Information technology, Management

The constituent Predicate Fact Pattern inferencing results determines whether the Inferencing Goal Event has occurred (or not occurred) followed by the emitting of the specified Consequent Actions."

Key Points: 
  • The constituent Predicate Fact Pattern inferencing results determines whether the Inferencing Goal Event has occurred (or not occurred) followed by the emitting of the specified Consequent Actions."
  • The latest Inferencing Agent version has been enhanced to support remote Fact Pattern invocations, with asynchronous response handling.
  • Asynchronous response handling will allow the inferencing routines to be situated in any network addressable platform, instead of as an integral part of the Inferencing Agent itself.
  • The Capability & Coverage Knowledge Base is the key to the Inferencing Agent's access to mission-relevant sensor data and inferencing resources.

Hydrofarm and CEA Advisors Announce Strategic Alliance

Retrieved on: 
Thursday, June 8, 2023
Farmer, IGE, Food, SVP, Research, Marketing, CEA, Electronics

SHOEMAKERSVILLE, Pa., June 08, 2023 (GLOBE NEWSWIRE) -- Hydrofarm Holdings Group, Inc. (“Hydrofarm”), a leading manufacturer and distributor of equipment and supplies for controlled environment agriculture (“CEA”), today announced that it has entered into an exclusive strategic alliance with CEA Advisors, a global design/build consultancy to the vertical farming industry and manufacturer of Growtainers® and Growracks®, to accelerate their expansion into the growing and evolving CEA space for both food and non-food production.

Key Points: 
  • SHOEMAKERSVILLE, Pa., June 08, 2023 (GLOBE NEWSWIRE) -- Hydrofarm Holdings Group, Inc. (“Hydrofarm”), a leading manufacturer and distributor of equipment and supplies for controlled environment agriculture (“CEA”), today announced that it has entered into an exclusive strategic alliance with CEA Advisors, a global design/build consultancy to the vertical farming industry and manufacturer of Growtainers® and Growracks®, to accelerate their expansion into the growing and evolving CEA space for both food and non-food production.
  • “We are excited about our relationship with Glenn Behrman and CEA Advisors.
  • It will bring great enhancements to the creative solutions and support we provide to the CEA market,” said Chris Mayer, SVP and Head of Hydrofarm Commercial.
  • We believe that the CEA industry has tremendous potential, and we are very excited to have a 50-year veteran of the global horticulture industry on our team.”
    “Working with the Hydrofarm team, IGE, and Chris Mayer is a dream come true for a company like CEA Advisors,” said Glenn.

Asian and Pacific Islander American Scholars (APIA Scholars) Meet with Congressman Kilili Sablan, Congresswoman Uifa'atali Amata, and Congressman James Moylan

Retrieved on: 
Friday, March 17, 2023
Member of Congress, University, Senior, The American Scholar, Research, Native Hawaiians, APIA, NHPI, AANHPI, IGE, Student, UCLA, SVP, Management, Education

WASHINGTON, March 17, 2023 /PRNewswire-PRWeb/ -- APIA Scholars (Asian Pacific Islander American Scholars) thanks Congressman Kilili Sablan, Congresswoman Uifa'atali Amata, and Congressman James Moylan for meeting our Board Member Former Congressman Robert Underwood, President Noel Harmon, Senior Vice President Julie Ajinkya, and Senior Director of Research & Pacific Island Partnerships Florie Mendiola to discuss the needs of Pacific Islander students throughout the US and in the Pacific region in higher education earlier this month on March 8.

Key Points: 
  • Within the Native Hawaiian and Pacific Islander communities, the proportion of adults who have not enrolled in any postsecondary education is particularly high.
  • We are committed to reducing the financial barriers for AANHPI students not only through scholarships but also through partnerships and applied research.
  • We look forward to having more productive discussions like the one we had with Congressman Sablan, Congresswoman Amata, and Congressman Moylan."
  • Wendy Wong, Asian Pacific Islander American Scholars, 1 3108698120, [email protected]

NeuroPace Announces First Patient Implanted in NAUTILUS Pivotal Study for the Treatment of Idiopathic Generalized Epilepsy (IGE)

Retrieved on: 
Tuesday, October 11, 2022
General Health, Medical Devices, Health, Pharmaceutical, Clinical Trials, Quality of life, Physician, U.S. Securities and Exchange Commission, Seizure, Insurance, Autism, Form 10-Q, SEC, Growth, Population, IGE, Diagnosis, Multiple sclerosis, Anticonvulsant, Nocturnal epilepsy, Family, Cognition, Annual report, Patient, Lists of diseases, Program, Idiopathic generalized epilepsy, Depression, EEG, Responsive neurostimulation device, Financial condition report, Result, Epilepsy, Trial of the century, Analysis, MD, Doctor of Philosophy, Cerebral palsy, Health, Safety, Ageing, Injury, Conditional sentence, Brain, Forward-looking statement, Binary relation, SUDEP, Death, Failure, FDA, Consciousness, Pharmaceutical industry, Residential care, Medical device

The pivotal study will evaluate the safety and effectiveness of the RNS System in individuals aged 12 and older with drug-resistant idiopathic generalized epilepsy (IGE), also known as primary generalized epilepsy.

Key Points: 
  • The pivotal study will evaluate the safety and effectiveness of the RNS System in individuals aged 12 and older with drug-resistant idiopathic generalized epilepsy (IGE), also known as primary generalized epilepsy.
  • Today, we have limited treatment options for patients who have drug-resistant, idiopathic generalized epilepsy, said Dr. Crudele.
  • Idiopathic Generalized Epilepsy (IGE) is the second most common type of epilepsy, after focal onset epilepsy1.
  • Bonnie, who has had drug-resistant epilepsy since infancy, was the first patient treated in the NAUTILUS study.

Xalles Studio is Collaborating with the University of California San Diego to Assist Early Stage Technology Companies

Retrieved on: 
Monday, May 9, 2022
University of California, San Diego, University, OTC, IGE, Securities Exchange Act of 1934, Solution, Technology, Forward-looking statement, UC, Company, Securities Act of 1933, Uncertainty, Hotbed, TAM, U.S. Securities and Exchange Commission, Security (finance), Korea, UC San Diego Health, Acquisition, GLOBE, Invention, Terminology, OTC Markets Group, Video game

WASHINGTON, DC, May 09, 2022 (GLOBE NEWSWIRE) -- via NewMediaWire -- Xalles Holdings Inc. (OTC: XALL), a fintech holding company providing innovative technology and financial services solutions, today announces that Xalles Studio has partnered with the Institute for the Global Entrepreneur (IGE) at the University of Calfornia San Diego (UC San Diego) Jacob School of Engineering (JSOE) to accelerate early-stage and startup technology companies.

Key Points: 
  • (OTC: XALL),afintechholdingcompanyprovidinginnovativetechnologyandfinancialservicessolutions, today announces that XallesStudiohaspartneredwiththeInstitutefortheGlobalEntrepreneur(IGE)atthe University of Calfornia San Diego (UCSanDiego)JacobSchoolofEngineering(JSOE)toaccelerate early-stage and startup technology companies.
  • XallesStudio,abusinessunitofXallesCapitalInc.,isanacceleratorprogramfocusedonhelpingearly-stage technologycompaniesreachtheirnextfinancialtransactionevent.XallesStudiolaunchedin2021withits initial 4 companyparticipantsandexpectsfastergrowthin2022throughitsnewlyformedrelationshipwith UC San Diego and IGE.
  • IGEcollaborateswithJacobsSchoolresearchcenters,partners,andresourcesacrosscampustohelpadvance innovative technologiesfromthelabtotheglobalmarketplace.Tothatend,IGEalsomaintainsastrongglobal networkthroughengagementswithuniversitycollaboratorsandindustrypartnersinJapanandKorea,and most recently, withsustainabilitypartnersinEurope.IGEstartupsrangefrommedicaltechnologiesto cleantech/energy.
  • For moreinformation,visitourwebsiteat www.xalles.com
    The InstitutefortheGlobalEntrepreneur(IGE) isaformalcollaborationbetweentheUCSan Diego Jacobs SchoolofEngineeringandRadySchoolofManagement,inspiringandtraining entrepreneurial leaders and catalyzing the translationofUCSanDiegotechnologiestofuelthe economy and benefit society.

Immunoglobulins Global Market Report 2021: COVID-19 Implications and Growth to 2025 & 2030 - ResearchAndMarkets.com

Retrieved on: 
Thursday, December 2, 2021
Biotechnology, Pharmaceutical, Health, Clinical Trials, Antibody, MAB, Asia, Allergy, Chronic inflammatory demyelinating polyneuropathy, Acquisition, Bacteria, Saliva, IGG, Clazakizumab, Antigen, Virus, Myasthenia gravis, Blood, Laboratory, COVID-19, Immunoglobulin G, Hypogammaglobulinemia, Research, Risk, Purpura, IGE, CSL Behring, Organization, IGD, III, Lymph, Infection, CIDP, ITP, IGA, IGM, B cell, Vaccine, Blood product

The "Immunoglobulins Global Market Report 2021: COVID-19 Implications and Growth" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Immunoglobulins Global Market Report 2021: COVID-19 Implications and Growth" report has been added to ResearchAndMarkets.com's offering.
  • The immunoglobulins market consists of sales of immunoglobulins by entities (organizations, sole traders, and partnerships) that are used to measure the level of types of antibodies in the blood.
  • The launch of new offices and laboratories to boost research and development activities is shaping the immunoglobulins market.
  • Thus, the increasing geriatric population is expected to increase the demand for the immunoglobulins market during the forecast period.

NeuroPace Receives IDE Approval to Initiate NAUTILUS Pivotal Study of its RNS System for Idiopathic Generalized Epilepsy

Retrieved on: 
Wednesday, November 10, 2021
Seizure, Health, Quality of life, Cognition, Safety, IGE, Population, Epilepsy, MD, IDE, Food, Insurance, EEG, Anticonvulsant, A Pale Debilitating Autumn, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Death, Responsive neurostimulation device, GLOBE, Disorder, Lists of diseases, Diagnosis, Program, Physician, Patient, Idiopathic generalized epilepsy, FDA, Brain, Pharmaceutical industry, Medical imaging

MOUNTAIN VIEW, Calif., Nov. 10, 2021 (GLOBE NEWSWIRE) -- NeuroPace, Inc., a medical technology company dedicated to transforming the lives of people suffering from epilepsy, today announced that it has received an Investigational Device Exemption (IDE) from the U.S. Food and Drug Administration (FDA) to study the company’s RNS® System in patients with drug-resistant idiopathic generalized epilepsy.

Key Points: 
  • The NAUTILUS pivotal study will be the first in the United States to evaluate use of brain-responsive neuromodulation for the treatment of IGE.
  • We are pleased with FDAs decision to grant IDE approval for the pivotal study, allowing us to evaluate the safety and effectiveness of the RNS System in patients who are living with drug-resistant, idiopathic generalized epilepsy, said Martha Morrell, MD, Chief Medical Officer of NeuroPace.
  • In March 2021, the company received Breakthrough Device Designation status from the FDA for the potential use of its RNS System to treat idiopathic generalized epilepsy.
  • The RNS System, a paradigm-shifting treatment for drug-resistant focal epilepsy, is the only brain-responsive neuromodulation system approved by the FDA.